超低剂量计算机断层扫描(CT)方案引导冷冻消融治疗T1a期肾细胞癌(RCC):辐射剂量与治疗结局
本研究在2023年1月至2024年1月间对30例经活检证实的T1a期肾细胞癌患者行超低剂量CT引导冷冻消融(120 kVp、50 mA、2.4 mGy),评估辐射剂量与肿瘤学结局。中位剂量长度乘积为442.3 mGy·cm,中位有效剂量为6.6 mSv;靶向与监测阶段的剂量参数显著高于计划与普查阶段(P<0.001)。1年局部肿瘤无进展生存率为96.7%(29/30),结论认为超低剂量CT引导冷冻消融有助于显著降低剂量而不影响小肾细胞癌的肿瘤学结局。
要点
- 超低剂量CT方案(120 kVp、50 mA、2.4 mGy)可用于引导T1a期肾细胞癌冷冻消融。
- 靶向和监测阶段的剂量、扫描次数、总电流和曝光时间显著高于计划与普查阶段(P<0.001)。
- 1年局部肿瘤无进展生存率为96.7%(29/30)。
核心结论
- 超低剂量CT引导冷冻消融有助于显著降低剂量,且不损害小肾细胞癌的肿瘤学结局。
研究设计与样本
- 研究纳入2023年1月至2024年1月间30例经活检证实的T1a期肾细胞癌患者,共30个病灶,行CT引导冷冻消融,采用120 kVp、50 mA、2.4 mGy方案;冷冻消融过程包括计划、靶向、监测和普查阶段;计算剂量长度乘积(DLP)、估计有效剂量(eED)、扫描次数、扫描范围、总电流和曝光时间;采用Kaplan-Meier分析计算1年局部肿瘤无进展生存率;采用非参数方差分析及Dunn多重比较比较辐射剂量和CT参数。
诊断标准与关键数值
- 每次治疗的中位DLP为442.3 mGy·cm(范围287.1-897.8 mGy·cm),中位eED为6.6 mSv(范围4.3-13.5 mSv);1年局部肿瘤无进展生存率为96.7%(29/30)。
临床应用与阅片要点
- 作者认为超低剂量CT引导冷冻消融有助于显著降低剂量,且不损害小肾细胞癌的肿瘤学结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: The purpose of this study was to evaluate the utility of an ultra-low-dose computed tomography (CT) protocol in guiding cryoablation and oncologic outcomes in the treatment of small renal cell carcinoma (RCC).
MATERIALS AND METHODS: CT-guided cryoablation using 120 kvp, 50 mA and 2.4 mGy was performed in 30 patients with 30 biopsy-proven T1a-RCCs between January 2023 and January 2024. Cryoablation procedures consisted of planning, targeting, monitoring, and survey phases. The dose-length product (DLP), estimated effective dose (eED), number of scans, scan ranges, total current, and exposure time of cryoablation phases were presented. The one-year local tumour progression (LTP)-free survival rate was calculated by Kaplan-Meier analysis. Nonparametric ANOVA with Dunn's multiple comparisons was used to compare radiation dose and CT parameters.
RESULTS: The median DLP and eED per session were 442.3 mGy·cm (287.1-897.8 mGy·cm) and 6.6 mSv (4.3-13.5 mSv), respectively. The DLP, eED, number of scans, total current, and exposure time in the targeting and monitoring phases were significantly higher than those in the planning and survey phases (P < 0.001). The scan ranges in the targeting and monitoring phases were smaller than those in the planning and survey phases (P < 0.001). The one-year LTP-free survival rate was 96.7% (29/30).
CONCLUSION: Ultra-low-dose CT-guided cryoablation contributes to significant dose reduction without compromising oncologic outcomes of small RCCs.
引用
- Park BK. Ultra-low-dose computed tomography (CT) protocol for guiding cryoablation in treating a T1a renal cell carcinoma (RCC): radiation doses and treatment outcomes. Clin Radiol. 2025. PMID: 41270495. doi:10.1016/j.crad.2025.107124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。